Sandoz enters agreement with Kit Check to track, automate restocking of products in U.S. hospitals

  • Sandoz and Kit Check will help hospital pharmacies cut costs, reduce risk, and better support hospital staff in treating their patients safely and more efficiently
  • Collaboration will optimize supply chain by providing real-time inventory reports, plus timely tracking of recalls and expiration of products
  • Kit Check™ uses powerful machine learning and advanced tracking technology to streamline medication inventory, workflow, and auditing processes

Princeton, New Jersey, June 27, 2019 – Sandoz Inc, a Novartis …

/by

New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy

  • Data show switching to Hyrimoz® (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis[1]
     
  • ADMYRA data reinforces review summarizing 90+ publications, that switching from reference …
/by

Sandoz announces plan to improve competitiveness and realign the organization, to drive ongoing Transformation and support future growth

  • Two-stage strategic Transformation plan foresees measures for organizational realignment, followed by increased investments to drive growth segments
  • Realignment of organization involves a planned reduction of global workforce by approximately 900 FTEs, including closure of Holzkirchen development center

HOLZKIRCHEN, May 15, 2019 – Sandoz today announces plans for a leaner and more efficient global organization, to drive cost competitiveness as the first stage of its ongoing strategic Transformation and support investments into future growth. …

/by

Sandoz demonstrates strategic focus on China, with first-of-a-kind generic approval under Quality Consistency Evaluation system

  • Sandoz receives generic approval for Rosuvastatin from China’s National Medical Products Administration (NMPA) under Quality Consistency Evaluation (QCE) system
  • Generic approval under China’s recently introduced QCE system is first of a kind for multinational pharmaceutical company
  • Regulatory milestone demonstrates long-term strategic focus on pioneering access to high-quality medicines in world’s largest, and rapidly-growing, generics market

Holzkirchen, Germany, May 9, 2019 – Sandoz today announced that it …

/by

Sandoz demonstrates strategic focus on China, with first-of-a-kind generic approval under Quality Consistency Evaluation system

  • Sandoz receives generic approval for Rosuvastatin from China’s National Medical Products Administration (NMPA) under Quality Consistency Evaluation (QCE) system
  • Generic approval under China’s recently introduced QCE system is first of a kind for multinational pharmaceutical company
  • Regulatory milestone demonstrates long-term strategic focus on pioneering access to high-quality medicines in world’s largest, and rapidly-growing, generics market

Holzkirchen, Germany, May 9, 2019 – Sandoz today announced that it …

/by

Sandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumors

  • Collaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumors
  • Per licence agreement, EirGenix, Inc is responsible for development and manufacturing; Sandoz has right to commercialize in all markets except China and Taiwan
  • Agreement is third announced biosimilars collaboration for Sandoz in 18 months; will build on robust portfolio of eight approved molecules, with a further 10-plus in development

Holzkirchen, Germany, …

/by

Sandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumors

  • Collaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumors
  • Per licence agreement, EirGenix, Inc is responsible for development and manufacturing; Sandoz has right to commercialize in all markets except China and Taiwan
  • Agreement is third announced biosimilars collaboration for Sandoz in 18 months; will build on robust portfolio of eight approved molecules, with a further 10-plus in development

Holzkirchen, Germany, …

/by

Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded

  • Transformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations[2]
  • Continuing operations net sales up 7% (cc[1], +2% USD) driven by Innovative Medicines:
    • Cosentyx was USD 791 million, +41% (cc) with strong demand growth in all indications and regions
    • Entresto grew to USD 357 million, +85% (cc) including the benefit from new data on hospital initiation
    • Oncology sales grew 9% (cc) mainly driven by Lutathera (USD 106 million), Promacta (USD …
/by

Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded

  • Transformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations[2]
  • Continuing operations net sales up 7% (cc[1], +2% USD) driven by Innovative Medicines:
    • Cosentyx was USD 791 million, +41% (cc) with strong demand growth in all indications and regions
    • Entresto grew to USD 357 million, +85% (cc) including the benefit from new data on hospital initiation
    • Oncology sales grew 9% (cc) mainly driven by Lutathera (USD 106 million), Promacta (USD …
/by

Sandoz drives differentiated portfolio with deal to commercialize new treatment for Opioid-Induced Constipation in key European countries

  • Agreement with Shionogi to commercialize Rizmoic® (naldemedine) in Germany, UK and Netherlands, plus right of first refusal for certain other European markets
  • Rizmoic® is an innovative medicine for treating constipation caused by opioid pain relief medicines, in patients who have previously been treated with a laxative
  • Agreement reinforces Sandoz anti-pain franchise and commitment to pioneer access to healthcare in areas of unmet medical need

HOLZKIRCHEN, April 11 2019 – Sandoz today announces that it has …

/by